drugset / Trial / NCT01528787
Study of AR-13324 in Patients With Elevated Intraocular Pressure
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days. The first dose and last dose will be administered in the clinic. Ocular safety and ocular hypotensive efficacy will be evaluated in the clinic throughout the study.
Timeline
- Start
- 2012-03
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Netarsudil | Small molecule | 0.01 % | Other |
| Subject | Netarsudil | Small molecule | 0.02 % | Other |
| Subject | Netarsudil | Small molecule | 0.04 % | Other |